{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:48:23Z","timestamp":1772239703995,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.fjurol.2024.102704","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T20:56:28Z","timestamp":1721854588000},"page":"102704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Perioperative chemotherapy and immunotherapy to optimize cystectomy outcomes in the curative intent of non-metastatic muscle-invasive bladder cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"34","author":[{"given":"Ismail","family":"Boutaleb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Mjaess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5377-8137","authenticated-orcid":false,"given":"Thierry","family":"Roumegu\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.fjurol.2024.102704_bib0270","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.fjurol.2024.102704_bib0275","series-title":"Edn. presented at the EAU Annual Congress Amsterdam","year":"2022"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102704_bib0280","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102704_bib0285","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1586\/14737159.2014.908119","article-title":"Circulating tumor cells in early bladder cancer: insight into micrometastatic disease","volume":"14","author":"Raimondi","year":"2014","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102704_bib0290","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data","volume":"48","author":"Vale","year":"2005","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102704_bib0295","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.fjurol.2024.102704_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/746298","article-title":"Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions","volume":"2014","author":"Cowan","year":"2014","journal-title":"Adv Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102704_bib0305","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","article-title":"Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials","volume":"81","author":"Burdett","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102704_bib0310","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eururo.2008.07.018","article-title":"Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience","volume":"55","author":"Donat","year":"2009","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102704_bib0315","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102704_bib0320","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.fjurol.2024.102704_bib0325","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.fjurol.2024.102704_bib0330","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.fjurol.2024.102704_bib0335","series-title":"robvis: an R package and web application for visualising risk-of-bias assessments","author":"McGuinness","year":"2019"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102704_bib0340","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/028418602320405041","article-title":"Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours","volume":"41","author":"Sengel\u00f8v","year":"2002","journal-title":"Acta Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102704_bib0345","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/003655902762467567","article-title":"Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer\u00a0\u2013\u00a0Nordic Cystectomy Trial 2","volume":"36","author":"Sherif","year":"2002","journal-title":"Scand J Urol Nephrol"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102704_bib0350","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.fjurol.2024.102704_bib0355","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International Phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 Trial","volume":"29","author":"the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group","year":"2011","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102704_bib0360","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/annonc\/mdu126","volume":"25","author":"Kitamura","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102704_bib0365","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102704_bib0370","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.eururo.2014.09.007","article-title":"Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"67","author":"Zargar","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102704_bib0375","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-5347(17)32822-7","article-title":"Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial","volume":"152","author":"Studer","year":"1994","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102704_bib0380","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00005392-199501000-00019","article-title":"Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience","volume":"153","author":"Stockle","year":"1995","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102704_bib0390","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0022-5347(01)66430-9","article-title":"A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer","volume":"155","author":"Freiha","year":"1996","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102704_bib0385","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1464-410X.2006.05859.x","article-title":"Complete long-term survival data from a trial of adjuvant chemotherapy vs. control after radical cystectomy for locally advanced bladder cancer","volume":"97","author":"Lehmann","year":"2006","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102704_bib0395","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/annonc\/mdr354","article-title":"Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial","volume":"23","author":"Cognetti","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102704_bib0400","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102704_bib0405","article-title":"Long-term results of a single-center prospective randomized trial assessing efficacy of a shortened course of adjuvant chemotherapy after radical cystectomy in patients with locally advanced bladder cancer","author":"Zhegalik","year":"2020","journal-title":"Cent Eur J Urol [Internet]"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102704_bib0410","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.2015.64.1076","article-title":"Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer","volume":"34","author":"Galsky","year":"2016","journal-title":"JCO"},{"issue":"34","key":"10.1016\/j.fjurol.2024.102704_bib0415","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102704_bib0420","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102704_bib0430","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102704_bib0425","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.annonc.2020.09.011","article-title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study","volume":"31","author":"Bandini","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102704_bib0435","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102704_bib0440","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102704_bib0445","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1186\/s12885-021-08990-3","article-title":"Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004\u00a0\u2013\u00a0AURA trial)","volume":"21","author":"Martinez Chanza","year":"2021","journal-title":"BMC Cancer"},{"issue":"24","key":"10.1016\/j.fjurol.2024.102704_bib0450","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2217\/fon-2021-0273","article-title":"Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: phase III KEYNOTE-866 and KEYNOTE-905\/EV-303","volume":"17","author":"Galsky","year":"2021","journal-title":"Future Oncol"},{"issue":"6_suppl.","key":"10.1016\/j.fjurol.2024.102704_bib0455","doi-asserted-by":"crossref","first-page":"TPS505","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS505","volume":"39","author":"Powles","year":"2021","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102704_bib0460","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102704_bib0470","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","article-title":"Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102704_bib0475","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"issue":"5b","key":"10.1016\/j.fjurol.2024.102704_bib0480","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1111\/bju.12274","article-title":"Eligibility for neoadjuvant\/adjuvant cisplatin-based chemotherapy among radical cystectomy patients: Cisplatin use in bladder cancer","volume":"113","author":"Thompson","year":"2014","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102704_bib0485","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.eururo.2014.01.014","article-title":"The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study","volume":"66","author":"Gandaglia","year":"2014","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.fjurol.2024.102704_bib0465","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102704_bib0490","first-page":"456","article-title":"Toxicity and surgical complication rates of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer undergoing radical cystectomy: updated safety results from the ABACUS Trial Euro","volume":"4","author":"Szabados","year":"2021","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102704_bib0495","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.eururo.2019.12.019","article-title":"Surgical safety of radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab in patients with bladder cancer: prospective assessment of perioperative outcomes from the PURE-01 Trial","volume":"77","author":"Briganti","year":"2020","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102704_bib0500","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.3390\/cancers15061742","article-title":"Refining the characterization and outcome of pathological complete responders after neoadjuvant chemotherapy for muscle-invasive bladder cancer: lessons from the randomized phase III VESPER (GETUG-AFU V05) Trial","volume":"15","author":"Culine","year":"2023","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102704_bib0505","doi-asserted-by":"crossref","first-page":"100785","DOI":"10.1016\/j.xcrm.2022.100785","article-title":"Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: a multi-center real-world retrospective study","volume":"3","author":"Hu","year":"2022","journal-title":"Cell Rep Med"},{"issue":"15_suppl.","key":"10.1016\/j.fjurol.2024.102704_bib0510","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1200\/JCO.2020.38.15_suppl.5047","article-title":"Phase Ib\/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): final results from the cisplatin (C)-eligible cohort of HCRN GU14-188","volume":"38","author":"Hoimes","year":"2020","journal-title":"JCO"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102704_bib0515","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial","volume":"40","author":"Funt","year":"2022","journal-title":"JCO"},{"issue":"7867","key":"10.1016\/j.fjurol.2024.102704_bib0520","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102704_bib0525","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102704_bib0530","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295039302400161X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295039302400161X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T02:21:14Z","timestamp":1726453274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295039302400161X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S295039302400161X"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102704","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative chemotherapy and immunotherapy to optimize cystectomy outcomes in the curative intent of non-metastatic muscle-invasive bladder cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102704"}}